LongBio Pharma (Suzhou) Co., Ltd. has issued a notice convening its 2025 Annual General Meeting (AGM) for 4:00 p.m. on 30 June 2026 at the company’s headquarters (5th Floor, Building F, Area A, No. 128 Yinhe Road, Dongnan Subdistrict, Changshu City, Suzhou, Jiangsu Province).

Key matters to be tabled:

1. Statutory accounts • Shareholders will consider and adopt the accountant’s report for the financial year ended 31 December 2025.

2. Profit distribution • The board will present the 2025 profit distribution plan for shareholder approval.

3. Auditor re-appointment • Ernst & Young is nominated to serve as the external auditor for the 2026 financial year, with the board authorised to fix its remuneration.

4. General mandates • A special resolution seeks authority for the board to issue new shares. • A separate special resolution requests authority to repurchase H shares.

Voting arrangements:

• The register of members will be closed from 25 June 2026 to 30 June 2026 (both days inclusive); no share transfers will be registered during this period. Shareholders recorded on 30 June 2026 are entitled to attend and vote. • Proxy forms and supporting documents must reach Tricor Investor Services Limited (17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong) no later than 4:00 p.m. on 29 June 2026. • All resolutions will be decided by poll, with results disclosed on the websites of Hong Kong Exchanges and Clearing Limited and the company.

Board composition:

As at the notice date (9 June 2026), the board comprises three executive directors (Dr. Liu Heng, Dr. Sun Bill Nai-chau, Mr. Xie Ming), four non-executive directors, and four independent non-executive directors.

Shareholders planning to attend the AGM are responsible for their own travel and accommodation expenses.